Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vortioxetine for Menopausal Depression
NCT02234362Phase 4Completed
- Sponsor
- Massachusetts General Hospital
- Start
- Jun 2015
- Primary completion
- Sep 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of vortioxetine in major depressive disorder (MDD), vasomotor symptoms, sponsored by Massachusetts General Hospital. Started Jun 2015; status: completed.
02
Drugs
vortioxetine
03
Conditions
major depressive disorder (MDD)vasomotor symptoms
Beyond the preview
Go deeper on NCT02234362.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02234362.